• / Free eNewsletters & Magazine
  • / My Account
Home>Binimetinib Continues To Advance In Clinical Development

Binimetinib Continues To Advance In Clinical Development

3party Content

Wed, 23 Apr 2014

Three Phase 3 Trials Advancing in Patients with BRAF Melanoma, NRAS Melanoma and Low-Grade Serous Ovarian CancerBOULDER, Colo., April 23, 2014 /PRNewswire/ -- Following the recent announcement by Novartis and GlaxoSmithKline that they have entered into a definitive agreement to exchange certain
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.